MZT2B is a centrosomal protein required for recruiting and assembling the gamma-tubulin ring complex (gTuRC), which nucleates microtubule formation during centrosome duplication and spindle assembly. Beyond this canonical role in cell division, MZT2B has emerged as an oncogenic driver across multiple cancer types. In non-small cell lung cancer (NSCLC), MZT2B is significantly upregulated and correlates with poor prognosis 1. Its depletion via genetic silencing or CRISPR/Cas9 knockout suppresses cell viability, proliferation, migration, and invasion while inducing G1-S arrest and apoptosis 1. Mechanistically, MZT2B promotes malignant phenotypes in NSCLC by enhancing mitochondrial respiration and ATP production, at least partially through upregulation of cytochrome c oxidase subunit 5B (COX5B) 1. MZT2B overexpression is also documented in gastric cancer, where elevated levels associate with advanced stage, metastasis, and H. pylori infection 2. In hepatocellular carcinoma, MZT2B co-expresses with NEDD1 in immunosuppressive macrophage subsets, suggesting roles in both tumor cells and the immune microenvironment 3. These findings establish MZT2B as a potential therapeutic target in multiple solid tumors, though specific inhibitor development remains to be pursued clinically.